Darbepoetin alfa belongs to a class of medications called erythropoiesis-regulating hormones. These medications are used to replace the erythropoietin that is lacking in people whose own body cannot produce enough.
Available form
Injectable, Injectable
Dosage
Manufacturer
Amgen
We won't bore you with the details, but Health Canada requires you to sign in.
By proceeding you agree to our Terms of Use & Privacy Policy
The usual recommended starting dose of darbepoetin alfa depends on body weight. Darbepoetin alfa is available only as an injection, which is given under the skin or into a vein. People who receive the medication under the skin can usually be taught to give themselves the injection. If this is the case, make sure you understand exactly how to do this, as instructed by your doctor or nurse. People who need to have the medication delivered into a vein must have the medication injected by a doctor or nurse.
The usual starting dose for adults with CKD is 0.45 µg per kilogram of body weight given once a week. Your doctor may need to adjust the dose according to your body's response to the medication. In some cases, doses can be given once every 2 weeks. Dose adjustments to find the right dose may be made 2 to 4 weeks after starting treatment and usually involve blood tests. Changes to the dose should not be made more often than every 4 weeks. If you are on hemodialysis, Aranesp (Darbepoetin-alfa) could also be given into the line connecting you to the hemodialysis machine.
The usual starting dose for adults with cancer is 2.25 µg per kilogram of body weight given once a week or 500 µg once every 3 weeks as an injection under the skin. Your doctor may need to adjust the dose according to your body's response to the medication. Dose adjustments to find the right dose may be made 2 to 6 weeks after starting treatment and usually involve blood tests.
Many things can affect the dose of a medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are being given the medication without consulting your doctor.
It is important to use Aranesp (Darbepoetin-alfa) exactly as prescribed by your doctor. If you miss a dose, contact your doctor or pharmacist to ask about what to do.
Store Aranesp (Darbepoetin-alfa) in the refrigerator between 2°C and 8°C, protect it from light, and keep it out of the reach of children. Do not freeze or shake Aranesp (Darbepoetin-alfa).
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes Aranesp (Darbepoetin-alfa). If you are concerned about side effects, discuss the risks and benefits of Aranesp (Darbepoetin-alfa) with your doctor.
The following side effects have been reported by at least 1% of people taking Aranesp (Darbepoetin-alfa). Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Although most of the side effects listed below don't happen very often, they could lead to serious problems if you do not check with your doctor or seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Stop taking the medication and seek immediate medical attention if any of the following occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Aranesp (Darbepoetin-alfa).
SingleJect Prefilled Syringes and Single-use Prefilled SureClickTM Autoinjector
Each Single Ject, prefilled syringe, or single-use, prefilled SureClickTM autoinjector contains: darbepoetin alfa as 10 µg, 15 µg, 20 µg, 30 µg, 40 µg, 50 µg, 60 µg, 80 µg, 100 µg, 130 µg, 150 µg, 200 µg, 250 µg, 300 µg, 400 µg, 500 µg per syringe in the following concentrations and fill volumes: 25 µg/mL in 0.4 mL; 40 µg/mL in 0.38 mL and 0.5 mL; 100 µg/mL in 0.3 mL, 0.4 mL and 0.5 mL; 200 µg/mL in 0.3 mL, 0.4 mL, 0.5 mL and 0.65 mL; 500 µg/mL in 0.3 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.8 mL and 1 mL. Nonmedicinal ingredients: polysorbate 80, sodium chloride, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate and sterile water for injection, USP. pH of polysorbate solution is 6.2±0.2. The needle cover of the prefilled syringe contains dry natural rubber (a derivative of latex).
To reduce the risk of accidental needle sticks to users, each prefilled syringe is equipped with an UltraSafe Needle Guard that is manually activated to cover the needle during disposal.
The autoinjector has a needle cover that automatically extends as the autoinjector is removed from the injection site after completion of the injection.
Single-dose Vials
Each single-dose vial, contains: darbepoetin alfa as 15 µg, 25 µg, 40 µg, 60 µg, 100 µg, 200 µg, 325 µg, 500 µg per vial in the following concentration and fill volumes: 15 µg/mL in 1 mL; 25 µg/mL in 1 mL; 40 µg/mL in 1 mL; 60 µg/mL in 1 mL; 100 µg/mL in 1 mL; 200 µg/mL in 1 mL; 325 µg/mL in 1 mL; 500 µg/mL in 1 mL. Nonmedicinal ingredients: polysorbate 80, sodium chloride, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate and sterile water for injection, USP. pH of polysorbate solution is 6.2±0.2.
Do not use Aranesp (Darbepoetin-alfa) if you:
Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications that you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them. Depending on your specific circumstances, your doctor may want you to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Before you begin taking a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should take Aranesp (Darbepoetin-alfa).
Health Canada has issued new restrictions concerning the use of Aranesp (darbepoetin alfa). To read the full Health Canada Advisory, visit Health Canada's web site at www.hc-sc.gc.ca.
Allergies: Aranesp (Darbepoetin-alfa) can cause severe allergic reactions. Contact your doctor immediately if you experience signs of an allergic reaction, such as skin rash, itching, difficulty breathing, or swelling of the face and throat.
Blood clots: Aranesp (Darbepoetin-alfa) may increase the chance of blood clot formation, causing reduction of blood flow to organs or the extremities, and which in some cases can cause death. Your doctor will monitor your hemoglobin level closely with blood tests during treatment with Aranesp (Darbepoetin-alfa). If you experience symptoms such as sharp pain and swelling in the leg, or difficulty breathing, contact your doctor immediately.
Cancer: Darbepoetin alfa is used to treat anemia caused by chemotherapy treatment of non-myeloid cancers. It is not used to treat anemia that is due to the cancer itself. Under some conditions, Aranesp (Darbepoetin-alfa) may cause tumours to progress or reoccur more quickly than for people who are not using darbepoetin alfa.
Cardiovascular disease: Aranesp (Darbepoetin-alfa) often affects blood pressure and can contribute to symptoms of heart disease. If you have high blood pressure, heart disease such as heart failure, Angina, or a previous Heart Attack, discuss with your doctor how Aranesp (Darbepoetin-alfa) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Aranesp (Darbepoetin-alfa), and whether any special monitoring is needed. If you are taking blood pressure pills to control blood pressure, it is important to continue taking them regularly while you are on darbepoetin alfa. Your doctor will monitor your hemoglobin (the protein in red blood cells that carry oxygen) until an appropriate dose of darbepoetin alfa has been determined.
Kidney disease: Aranesp (Darbepoetin-alfa) may be used by people with chronic kidney disease who are receiving dialysis and who are not receiving dialysis - the dose may be different for each. Your doctor will monitor you closely for your response to the medication.
Pure red cell aplasia: Cases of pure red cell aplasia (PRCA) have been reported among people treated with darbepoetin alfa. PRCA is a condition in which a person's bone marrow stops producing red blood cells, leading to severe anemia. People who develop PRCA may experience a new or worsening feeling of tiredness or shortness of breath. If you are experiencing such symptoms, call your doctor as soon as possible. Do not stop your medication without contacting your doctor first.
Seizure: Aranesp (Darbepoetin-alfa) may contribute to an increase in seizures although the relationship between darbepoetin and seizures is not clear. If you experience seizures or have a history of seizure disorder, discuss with your doctor how Aranesp (Darbepoetin-alfa) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Aranesp (Darbepoetin-alfa), and whether any special monitoring is needed.
Stroke: Darbepoetin can increase the risk of blood clots forming in the blood vessels. If you have a past history of stroke, discuss with your doctor how Aranesp (Darbepoetin-alfa) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Aranesp (Darbepoetin-alfa), and whether any special monitoring is needed.
If you experience signs and symptoms of a stroke, blurred vision or difficulty speaking, sudden headache or loss of coordination, contact your doctor immediately.
Pregnancy: Aranesp (Darbepoetin-alfa) should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking Aranesp (Darbepoetin-alfa), contact your doctor immediately.
Breast-feeding: It is not known if darbepoetin alfa passes into breast milk. If you are a breast-feeding mother and are taking Aranesp (Darbepoetin-alfa), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
Children: The safety and effectiveness of using Aranesp (Darbepoetin-alfa) have not been established for children.
price lookup
Total no. of dose(s)
Manufacturer
Insurance coverage
Dosage
*Actual pricing may differ. Medication is only available by prescription. The cost may be subsidised by your provincial or private health plan.
price details
Total (CAD)
--*
Drug info not available
It’s like having us in your pocket, putting you first in every interaction.
Your medication is delivered to you at no added cost.
Call, text, email—whatever works for you. We’re humans, ready to help.
Discreet with real-time updates. Go about your day, your meds are on the way.
Your region
,
Pocketpills is licensed by
Accreditation No
#
Pharmacy Manager
2025 Pocketpills
Pocketpills is not a pharmacy
or a drug manufacturer